1. HER2-XPAT, a novel protease-activatable pro-drug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP). (October 2020) Authors: Cattaruza, F.; Koski, C.; Nazeer, Å.; Lange, Z.; Henkensiefken, A.; Hammond, M.; Derynck, M.; Schellenberger, V.; Irving, B. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗